PropertyValue
?:abstract
  • The approval came despite the World Health Organization’s Solidarity trial reporting that the drug had little to no effect on 28 day mortality and did not delay the need for ventilation or shorten patients’ stay in hospital 1 The study, which is available as a preprint and has not yet been peer reviewed, included more than 11 000 adults in 405 hospitals across 30 countries, of whom 2750 were randomly allocated to receive remdesivir 2 Remdesivir was developed by Gilead Sciences with $70m in US government funding The new approval covers most but not all patients previously included in the emergency use authorisation Because of this, the FDA decided to reissue an emergency use authorisation to allow remdesivir to be used to treat children in hospital weighing 3 5 kg to 40 kg and those under 12 years weighing at least 3 5 kg The results, published in the New England Journal of Medicine,5 reported that patients who received remdesivir had a median recovery time of 10 days (95% confidence interval 9 to 11 days), whereas it was 15 days (13 to 18 days) in the placebo group
is ?:annotates of
?:creator
?:journal
  • BMJ_:_British_Medical_Journal_(Online)
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Covid-19: US approves remdesivir despite WHO trial showing lack of efficacy
?:type
?:who_covidence_id
  • #889889
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/s3tpoquc>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/s3tpoquc>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all